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Making Research
a Requirement of Treatment
Why We Should Sometimes Let Doctors Pressure Patients
to Participate in Research

by DAVID ORENTLICHER

When a patient could be offered one of multiple established treatments, doctors should be able to
offer treatment only if the patient agrees to participate in research aimed at determining which of the
treatments is most effective. Making treatment conditional on research participation will help researchers

complete badly needed studies.

In recent years, a number of events have raised
concerns about the adequacy of safeguards to
protect people who volunteer for medical re-

At the same time, we must also question whether
research safeguards are sometimes overly protective
of people who might enter clinical trials. Progress in

search. Individuals without a serious illness, like treating trauma patients, for example, was hampered
for many years by the requirements of informed
Jesse Gelsinger and Ellen Roche, have died unexpectedly while participating in clinical trials.' The consent-seriously injured patients often lack the
federal Office for Human Research Protections tem- decision-making capacity necessary to agree to enporarily halted studies at several major academic
centers for their failure to observe research guide-

rollment in a research trial, and family members may

lines.2 Overseas trials of HIV-therapy during preg-

half. These difficulties in enrolling patients slowed

nancy have been criticized for including a placebo

the development of promising therapies-including

whether research subjects are placed at too great a

substitutes for blood to transfuse patients who have

risk by physicians seeking to advance medical

suffered major blood loss.4 To address this problem,

knowledge.

federal guidelines for informed consent were modi-

not be available to consent to the trial on their be-

control arm.3 For some studies, we must worry more effective methods for cardiac resuscitation and

fied in 1996 to permit valuable research in the emergency setting.5

This article argues that just as there was a need to
relax the requirements of informed consent for trau-

David Orendicher, "Making Research a Requirement of Treatment:

maParticresearch, there is a need to relax the precautions
Why We Should Sometimes Let Doctors Pressure Patients to
ipate in Research," Hastings Center Report 35, no. 5 (2005):taken
20-28.
to ensure voluntary participation of subjects in
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another kind of research trial-studies involving the comparison of two
or more established therapies to see
whether one is superior to the alter-

native(s). For many medical problems, physicians can choose among
multiple therapeutic options, and the

Researchers and trial sponsorsHypothetical Case Study
have employed a number of ap-

proaches to address the difficulties inAs an illustration of the concern
with current standards for inrecruiting patients for clinical trials.

Some have employed more intensiveformed consent in research, consider
recruitment practices, including no-the following hypothetical case study,
tices on radio and television.12 Otherswhich is based on an important, fed-

choice is typically based more on

have taken their trials overseas, whereerally funded cinical trial.
recruitment is often easier.13 But these The cinical trial was the Atrial

benefit greatly from studies that cari-

alternatives are either insufficientlyFibrillation Follow-up Investigation
effectivel4 or raise their own ethicalof Rhythm Management (AFFIRM)

hunch than on data. Patients would

fy the relative benefits and risks of
different options for their illnesses.

concerns.15

However, these studies can be de-

layed-and medical progress impeded-by difficulties in securing the
participation of enough individuals.6

trial.16 Sponsored by the National

This article argues on behalf of an- Heart, Lung, and Blood Institute,

other way to increase patient enroll-AFFIRM compared two established
ment in clinical trials: It should be treatment strategies for persistent or
permissible for a physician to condi-recurrent atrial fibrillation to see if

In the AFFIRM study comparing the

tion a patient's access to treatment onone offered either better outcomes or

two leading therapies for chronic atrial fibrillation, for example, only fifty-

adverse effects.17 In one strategy,
the patient's willingness to enter less
a
clinical trial when the trial comparesphysicians try to restore and maintain

five percent of patients invited to en-

two or more accepted therapies tothe atrium's normal sinus rhythm

roll in the study chose to do so.7 In a

with cardioversion (the application of
find out whether they are equivalent

study of alternative therapies for some

or whether one is better than the oth-an electrical shock to jolt an abnor-

chronic lung diseases (including asthma and emphysema), more than half

ers. That is, the physician should bemal heartbeat into a normal one) and
able to offer treatment to the patientantiarrhythmic drugs.18 This method
is known as "rhythm control." Alternatively, physicians can try to control

the response of the
If a patient did not want to participate, the cardiologist

hearts ventrices

to the atrial fibrillation by maintain-

ing a good ventricular heart rate-a
would decline to accept the patient for care or
would
method known as "rate control."
With this second strategy, physicians

end the patient-physician relationship and instruct
the
employ both
drug
patient to obtain care from another

and nonpharmacologic therapies.19 In the AFFIRM
cardiologist.
study, patients were randomized to
receive one of the two treatment

with total recruitment taking twice as

strategies, and the patients received
only in the setting of the cinical trial.their care from their current physiPatients who declined to participatecian according to the study protocol's
in the study would have to receiveguidelines. Thus, while the patients

long as expected (sixteen months in-

care from another physician.

of the patients invited to participate
in the study declined the invitation,

stead of eight months).8
Patients decline invitations to en-

roll for a number of reasons. Some

people are uncomfortable with the
idea of being part of a testing process,

or with the possibility that which
treatment they will receive will be de-

cided randomly.9 Many of these patients are concerned that the physicians are more interested in the re-

search study than in the patient's

were participating in a research trial,
Concerns about ensuring that pa-there was nothing experimental about
tients participate in research truly vol-their treatment. The only experimenuntarily discourage or prevent physi-tal part of the trial was the fact that a

cians from employing such a mea-patient's own treatment strategy was
sure. Conditioning treatment on achosen randomly. (Results from AFpatient's willingness to enroll in a trialFIRM were published in December
is thought to constitute unacceptable2002, and they suggested that rate
coercion. But in fact, linking treat-control has important advantages
ment to participation in researchover rhythm control as a therapeutic

could be a valuable and ethically
option.20)
Now assume one change in the

sound way to increase patient partici-

care.'0 Patients also cite concerns
pation, as long as the clinical trial in-trial. In the actual study, cardiologists
about the burden of extra tests and volves a comparison of alternative, es-invited patients with atrial fibrillation
to enter the AFFIRM trial. Patients
appointments and the uncertainty oftablished therapies.

the consequences for their health

who chose to enroll were assigned to

from participation."

one of the treatment strategies ran-
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domly. If a patient declined enrollment, then the cardiologist provided
one of the two treatment strategies ac-

cording to the cardiologist's usual
practice. But suppose instead that
some cardiologists told their patients
that they would treat the atrial fibrillation only if the patients enrolled in
the study. If a patient did not want to

participate in AFFIRM, the cardiologist would decline to accept the patient for care or would end the patient-physician relationship and instruct the patient to obtain care from

reduce blood pressure, ameliorate
that participation
deis voluntary, [that]
pression, or limit the damage refusal
from
to a
participate will involve no
penalty or loss of benefits to which
The condition that none of the
the
al- is otherwise entitled, and
subject

heart attack.

[that] the subject may discontinue
ternatives be "experimental" makes
the proposal in this article more
participation
cau- at any time without
penalty or loss of benefits to which
tious than a new policy of the Centers
for Medicare & Medicaid Services.
the subject is otherwise entitled."25

One could argue that enrollment
That policy links Medicare coverage
to patient participation in research would satisfy the federal requirement
trials. CMS designed the policy to of voluntary participation-a patient

systematically determine when could enter the trial or seek care from

Medicare should cover new and ex-

another cardiologist. Moreover, the

pensive treatments or diagnostic tests. patients would not be deprived of any

For example, coverage for new uses of benefits to which they were "otherapproved anticancer drugs has been wise entitled"-after all, a patient is
tion of receiving care from these car-conditioned on the willingness of pa- not entitled to obtain treatment from

another cardiologist. Participation in
AFFIRM would have been a condi-

tients to enroll in a cinical trial spon- any particular cardiologist. Rather,

diologists.
Before discussing the propriety of

such a condition, a couple of explanatory points are in order. First, in the

hypothetical trial, the informed con-

sent process would remain generally

sored by the National Cancer Insti- the patient-physician relationship is a
tute. But the CMS policy affects re- contractual one, based on the mutual
search on tests or treatments whose consent of patient and physician.26
Alternatively, one might concede
efficacy has not been established for
that physicians have no duty to take
the patients being studied.23

on a particular patient-that they

unchanged. The patients would be
given all of the information that nor-

Today's Research Guidelines

mally is given before enrolling in a
clinical trial, and the patient would
have the freedom to give or withhold
consent. The one difference with cur-

ing care. However, physicians cannot
deny care for bad reasons, and condiT nder current practice, it is highly
unlikely that approval would be
tioning treatment on a willingness to
participate in research might be congiven to a study in which physicians
a bad reason, just as denying
made participation in the study sidered
a
care because of a patient's race or sex
condition for receiving treatment.
constitutes a bad, and therefore unacStudies that involve testing or obser-

rent practice is that a decision not to
enroll in the trial would entail the

need to find another physician for

need not have a good reason for deny-

vation of people must be authorizedceptable, reason. Moreover, if a pa-

care.

byAFan institutional review boardtient already was receiving care from a
Second, the point of using
(IRB),
FIRM as an example is to presenta acommittee that reviews thecardiologist, a refusal to continue

treatment outside of the study would
proposed
study and considers
cinical trial in which patients are
ranwhether it meets ethical standards for
apparently constitute a penalty-a
domized between or among alternative treatments, when (1) eachmedical
of the research. For example, an
termination of care by the physician.

IRB would analyze the proposal to Still, even if a cardiologist ended
therapies is well accepted for treating
an existing patient-physician relationensure that participation in the study
patients (that is, none of the alternaship, one could say that no violation
is voluntary
and that the health of the
tives is considered "experimental"
or
volunteers
is not placed at too great of
a federal research rules had occurred.
substandard therapy)21 and (2)
data
Since physicians can end a patientrisk.24 For a study conditioning treatare lacking as to how the therapies
physician relationship with proper
ment
on participation in research,
compare in their ability to treat
the
notice,27 patients are not "otherwise
IRBs
would be concerned that potenpatients' disease. As a corollary,
there
entitled" to a particular physician's
tial
would be coerced into
should be genuine uncertainty
assubjects
to
care.
whether any of the treatments enrolling
is supe- in the trial-that a decision
rior or inferior to the others (atocondienroll would not be truly volun- International standards for re-

tary.
tion known as "dinical equipoise"22).

search are also ambiguous but give

Whether IRBs would be required
Many trials would meet these criteria.

more reason to reject the hypothetical

to reject
the hypothetical protocol is
For example, a study comparing
two
or more established drugs for arthritis
uncertain. According to the federal

protocol. According to the World

Medical Association's Declaration of

rules governing
research on human
might be conducted. Similarly,
re-

Helsinki, "the refusal of a patient to

ferent drugs used to lower cholesterol,
process must include "a statement

participate in a study must never interfere with the patient-physician re-

subjects,
searchers might want to compare
dif-the informed consent

22 HASTINGS CENTER REPORT
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Making a Change

lationship."28 It might be said that if

would enroll in a clinical trial to

physicians are not obligated to enter
into particular patient-physician relationships, then there is no "interfer-

avoid having health services with-

held.

N Ithough current practices discourage conditioning treatment

ence" when a physician decines to

Whether or not the hypothetical
version of AFFIRM would violate ex-

provide care. Yet withholding care if a

isting standards for medical research,

cians could make a strong case for

patient refuses to enter a study ap-

physicians and IRBs currently would

having the freedom to treat patients

pears to constitute interference.

be very reluctant to make enrollment
in a research trial a condition for re-

only in the setting of a cinical trial,
when a study is comparing well-established therapies.

The ethical guidelines of the
Council for International Organiza-

tions of Medical Sciences (CIOMS)
also suggest that the hypothetical
protocol would be unacceptable. In

ceiving care. There would have to be
a significant change in prevailing atti-

tudes before the hypothetical version

of AFFIRM could take place.

the commentary to the guideline on

To be sure, one can point to a

obtaining informed consent, the
CIOMS guidelines state:

common example in which IRBs already permit researchers to link participation in a clinical trial to access

Intimidation in any form invalidates informed consent. Prospec-

to treatment: Many patients with
cancer must agree to participate in a

on participation in research, physi-

iElminating unnecessary impediments to medicalprogress. When a
physician chooses between multiple

therapies without knowing which
therapy offers the greatest benefit, the

physician may be subjecting many
patients to inferior treatment. The
physician could use the different alternatives equally to ensure that at
least some patients receive the best

treatment, or the physician could

We might want to say that patients should be willing
make a best

guess as to the most ap-

propriate treatment, knowing that ei-

therif
all
to participate in new trials. To put it another way,

or none of the patients will re-

ceive the optimal therapy. (To be

sure, with
people want to share in the benefits of their society,

some conditions, one treat-

ment might work best for some pa-

tients, while another treatment might
they arguably should share in its burdens, too. work
best for others. But there will

tive subjects who are patients often

depend for medical care upon the

physician/researcher, who consequently has a certain credibility in

their eyes, and whose influence
over them may be considerable,
particularly if the study protocol

has a therapeutic component.
They may fear, for example, that

refusal to participate would damage the therapeutic relationship or
result in the withholding of health
services. The physician/investigator

must assure them that their decision on whether to participate will
not affect the therapeutic relation-

ship or other benefits to which
they are entitled ... .29

On the one hand, the guidelines
speak of maintaining "benefits to
which [patients] are entitled," and
patients are not entited to care from

any particular cardiologist. On the

cinical trial as a condition of receiv-

still be uncertainty as to which patients do better with which treat-

ing care. A patient may be referred to

ments.)

a specialized cancer center for treatment and find that treatment at the
center would entail enrollment in a
research study. Indeed, about 70 per-

The only way to ensure that all pa-

tients receive optimal therapy is to
run a clinical trial comparing the al-

ternatives. Moreover, the number

cent of children with cancer receive at

who receive inferior treatment can be

least some of their treatment through

a cinical trial sponsored by the Na-

minimized by completing the trial
rapidly. Physicians might therefore

tional Cancer Institute,30 and in order

want to enroll all of their patients in a

to receive treatment at the National

definitive study. If patients have the

Institutes of Health Clinical Center,

option of declining participation, the

patients must agree to participate in
medical research. An unwillingness to

study could take much longer,31 as in

enroll would result in the patient re-

lung disease for which recruitment
took twice as long as expected.32
Related to the interest in practic-

turning for care to the patient's treat-

ing physician. But the existence of
this practice in oncology and other
specialized areas does not change the
fact that physicians typically would
not decine to treat a patient outside
of a research protocol if the patient
refused to enroll in the physician's
clinical trial.

the study of treatment for chronic

ing medicine optimally is the interest
in professional autonomy. Just as it is

important for patients to have control over the decision of whether to
accept health care, it is important for

physicians to have control over
whom they treat and how they treat

other hand, the commentary explicit-

them. Thus, it is well recognized by

ly discusses the concern that patients

the law that the patient-physician re-

September-October 2005
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lationship is created only with the
voluntary consent of both patient
and physician,33 and that physicians
can choose the methods of surgery or
the types of drugs they will employ.
Note that the kinds of studies this

article suggests have a kinship with
the practices of hospitals at academic
medical centers.34 Patients can choose
care at a teaching hospital and accept
the condition that medical students
and residents will participate in their

care, or they can decide to go elsewhere for their care and avoid treatment by students and residents. In
other words, society already accepts
the idea that patient participation in
the achievement of an important so-

cial goal can sometimes be made a
condition of patient access to medical

tial, and substantial risks ought to be tive as the alternatives. In addition,

assumed only voluntarily. If society patients would be free to decine enwere to condition medical treatment rollment in the study and seek care
on enrollment in clinical trials, we from a different physician. As long as
would effectively create a moral duty the patient could indeed go someto participate in research. A volun- where else for medical care, no obligtary, supererogatory act would be ation to participate in research would
converted into an involuntary, oblig- exist.
atory act.

To be sure, we often impose social
obligations on the grounds that they
benefit everyone. Speed limits constrain my freedom when I drive, but
they also ensure my safety.36 Insisting

ot only are there strong grounds
for conditioning treatment on
the willingness of patients to partici-

that patients become research sub-

pate in some clinical trials, but the

jects, however, may entail a different
kind of sacrifice-that of one's health

usual justifications for strictly volun-

or life. And our society rejects the
idea that people should have to compromise their health for the sake of

the kinds of studies suggested by this
article.

others.37 Accordingly, we should hesi-

care.

Answering the Objections

to conclude that patients must
Encouraging more of a tate
social
assume the risks of medical research
sentiment in favor ofparticipation
for the benefit of other persons.
in medical research. Today's patients
This
conclusion is reinforced by
benefit greatly from the medical
dis-

tary participation are not present in

Risk to patient welfare is not a
concern. Most importantly, we do
not have to worry about patients
being forced to assume a risk to their

health. In many clinical trials, a pa-

tient may be randomized to either
standard therapy or experimental

coveries of yesterday, and those
the potential
disconsequences of creatcoveries would not have occurred
ing duties to participate in medical
without the willingness of previous research. If patients must become ingenerations of patients to volunteervolved in medical research as a condi-

and may have serious side effects. Pa-

benefits of earlier research, we might then some sick people will simply

arm of the study would be harmed by

want to say that patients should be forgo treatment.
Although real duties to participate
put it another way, if people want toin medical research are problematic,
share in the benefits of their society, the importance of medical research

their participation. Similarly, if an ex-

for clinical trials. In return for the tion of receiving medical treatment,

willing to participate in new trials. To

therapy. In such cases, the experimental therapy may not fulfill its promise

tients in the experimental therapy

perimental therapy is compared to
placebo when established treatments
already exist for the medical condi-

they arguably should share in its bur- suggests that society can do more to

tion being studied, patients in the

dens, too. Moreover, we might say, encourage in people an inclination to
no one is required to accept the bene-participate in clinical trials. Encourfits of medical treatment. Indeed, pa-aging more of a sentiment in favor of
tients enjoy a constitutional right toparticipation would be particularly
refuse medical treatment, even life- appropriate when (1) the risks to the

placebo arm and possibly in the ex-

sustaining treatment. Whether to re-individual are minimal and (2) there
ceive medical treatment remains an is an opportunity for patients to opt

option. As an option, its receipt out of the clinical study. Patients

could be made conditional on the
should not have a duty to risk their
willingness of the patient to partici- health for others, and to the extent
that they may feel that even a limited
pate in medical research.
On the other hand, it is question- obligation has been created, it should
able whether yesterday's research sub- be escapable.38 These qualifications

jects can by their altruism bind would be satisfied in the kinds of

perimental arm of the study will suffer by virtue of their participation in

the cinical trial.39 In studies compar-

ing well-accepted treatments, on the
other hand, the patient would be re-

ceiving the same care that would be
provided in a visit to a physician's office. In fact, the patient might receive
better care by virtue of enrollment in
the study; patients participating in re-

search studies receive greater attention to-and more rigorous observation of-their medical conditions

today's patients to similar acts of al- studies that this article suggests. No than do patients receiving care in
truism.35 Participation in medical re- patient would be subjected to a place- their physicians' offices.40

One might be concerned about
search is a morally praiseworthy act, bo or an experimental therapy.
denying
patients the opportunity to
but it is ordinarily not a morally re- Rather, all patients would be receivquired act. The risks of experimental ing a well-accepted therapy, which to weigh for themselves the advantages
drugs or procedures can be substan- the best of our knowledge is as effec- and disadvantages of the alternative
24 HASTINGS CENTER REPORT
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therapies and choose for themselves
which treatment to receive. Even if
there is no reason to think that one

purpose of the pressure is to encour-

age them to help society understand

some interest to which the patient

would otherwise be entided. Whether

and treat disease. There is nothing

the patient is worse off depends on

wrong with reasonable efforts at per-

whether the first physician has an un-

tients might find one therapy's side

suasion when the persuasion is de-

derlying obligation to care for the pa-

effects more distressing than those of

signed to foster socially desirable behavior.

earlier point that patients are not en-

therapy is superior, individual pa-

the alternative therapies. But I do not

believe that this concern, although it

In addition, studies comparing

tient,45 and this takes us back to the

titled to receive care from a particular

is legitimate, is decisive. Most pa-

well-established treatments lack the

tients defer to their physician's recom-

mendation rather than making their

worrisome elements present in situations that are condemned as coercive.

own choice. In addition, recall that

For example, people who choose to

ty to the argument against the hypothetical version of AFFIRM. Condi-

patients who do not want to enter the
trial are free to seek care from another

enroll in the study would not be dri-

tioning treatment on participation in

ven by desperation or by the lack of a

the study is said to be unacceptably

physician and be treated as they prefer. Their freedom to choose would

good alternative,42 nor would they
have succumbed to threats of physical

coercive because the patient would be
threatened with the loss of the physi-

be restricted only if they chose to re-

harm.43

cian. But the patient ordinarily lacks

ceive treatment from a physician involved in the cinical trial.

More precisely, when a physician
conditions treatment on a patient's

any entitlement to a particular pa-

The possibility of coercion is not

enrollment in a study comparing
well-established treatments, the

would have such an entitlement only
if care is denied for a bad reason. In

serious. Voluntary participation in

physician.
In other words, there is a circulari-

tient-physician relationship. She

identifying what would constitute a
bad reason, we must find something
Typically, patients are told they need not participate
in the mere denial of
that goes beyond
care-racial bias or exposure to a significant health risk, for example. If
medical research. But with studies comparing
the bad reason is simply the denial of
care, then
different, well-accepted treatments, it would not
bethe argument becomes circular.

By analogy, physicians also do not
troublesome if patients felt some pressure to enroll.
unduly coerce their patients by rais-

ing their fees. The physician effective-

medical research is important because

patients may be reluctant to reject
their physicians' invitation to enter a
research study. A patient might undu-

ly defer to the physician's judgment
because of the physician's greater ex-

physician is not presenting the patient with a threat. As Alan

ly tells patients that access to further

care will be denied unless the patient
Wertheimer observes, A threatens
B pay more for the care, and
agrees to
patients may be worse off for having
when the consequence of B's declinchange physicians if they cannot
ing A's proposal is that B will be toworse
off than B would otherwise be.44
afford the fee increase. Nevertheless,

pertise or because of fear that a refusal

However, the patient who declines to because the patient is not entitled to

to participate might jeopardize the

enroll in the study comparing well-es- care indefinitely at a fixed fee, a rea-

patient's relationship with the physi-

cian. Patients might easily feel that
they have no real choice when asked
to enroll in a study.41 As a result, eth-

ical guidelines for medical research
include provisions to assure patients
that they are free to choose not to

tablished therapies will not be worse sonable fee increase would not be
off for having refused. The patient considered unethical coercion.

will receive treatment with one of the

not invited the patient to enroll in the other perspective-what the patient
study.

To be sure, the patient who must

participate.
But with studies comparing differ-

find another physician after declining

ent, well-accepted treatments, it

enrollment may be worse off when

would not be troublesome if patients

compared with the alternative of de-

felt some pressure to enroll. If they

dining enrollment and still remaining

agreed to participate, they would not

with the physician. But that is not the

be placed at any greater risk of harm

relevant moral comparison. The issue

than if they did not. Moreover, the

is whether the patient is deprived of

September-October 2005

That the hypothetical study in-

therapies being studied, just as would volves a noncoercive offer rather than
have happened if the physician had a coercive threat can be seen from an-

would have to give up by enrolling in

the study. Consider in this regard
what the physician might say to a patient:

When I first started treating your
chronic atrial fibrillation, I mentioned two strategies for treatment,

rhythm control and rate control.

Many cardiologists and I prefer
HASTINGS CENTER REPORT 25
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rhythm control, but others prefer
rate control. As I also mentioned,
data are lacking as to which strate-

gy works better. There now is a
study comparing the two strate-

gies, and I believe it important
that the study be completed so

that we can find out if one of the
two strategies works better.

Accordingly, I will continue treat-

ing your atrial fibrillation if you
enroll in the study. If you do, then

whether you remain on rhythm
control or whether I treat you with
rate control instead will be decided

randomly. While you are in the
study, the costs of your atrial fibril-

lation treatment will be paid by
the study sponsor. If you do not
want to enroll in the study, I will

refer you to another cardiologist
who can continue with the

ticipation in research may simply
Concerns about patient trust are
have the effect of changing the especially
demoimportant in medical re-

graphics of the research subjects
to Medical research generally insearch.
include a more diverse patient volves
popu- patients accepting some risks
to their own health for the benefit of
lation.47 (The fact that conditioning
treatment on participation may future
result patients. Because medical rein a more diverse population of
re- is predicated on a sacrifice of
search
search subjects provides another
im- welfare, it is important to aspatient
portant reason for preferring this
sure
appatients that the risk will be

proach over other ways to promote
minimized. Moreover, past abuses of
participation, such as television
or welfare in research give papatient
radio advertising.48)
tients grounds for skepticism about
Note, too, that this article's the
protrustworthiness of today's reposal is less coercive to patientssearcher.
than
The Tuskegee syphilis
study50
and the radiation studies of
an alternative proposal, offered
by

Robert Truog and colleagues,cancer
thatpatients51 are two of the more
would entail waiving informednotable
con- examples of abuse.
While these concerns about trust
sent for trials that compare estabare important, they should not lead
lished therapies.49 Under that proposal, patients would be told about
us the
to reject entirely the possibility of

institution's policy of conducting
conditioning treatment on participa-

tion
in research. Past abuses in medcomparative clinical trials without
the

usual process of informed consent,
ical research involved two problematrhythm control strategy, and but
as
the patients would not be ic
asked
elements, neither of which is prenow, your insurer and you will be
for consent before their actual enrollsent in the kind of trial suggested by
responsible for the costs of your
article. First, many abusive studment into a comparative trial.this
As a

care.

ies involved
the deception of the recondition of receiving care at the
in-

stitution, patients would lose their
search subjects. They were not given
accurate information about the trials
ability
By going into the study, all the
pa- to choose whether to particitients would have to forgo would
patebe
in the institutions comparative
in which they were participating. As
trials.
their ability to choose between
two
previously indicated, the ability to
treatment strategies when no one Threat
re-

to patient trust. We

condition treatment on research par-

ally knows which strategy is more
might
debe concerned that condition-

ticipation would not entail any other

sirable. And in return for forgoing
ing treatment on participating in rethis choice, the patients might search
be rewould undermine patient trust
lieved of their financial obligations
in the medical profession. If patients
for the costs of care.46
felt coerced by their physicians' research
Moreover, if physicians were
to requirements, they would be
inclined to wonder whether their
condition treatment on participation

changes in the requirements of informed consent. Second, many of the

abusive trials placed patients at an
unacceptable risk to their health. In
contrast, the kinds of studies that sat-

isfy this artice's proposal are those in

were compromising their which patients would receive one of
in research, they might be less physicians
likely
to encourage participation in a interests
biased for the benefit of other inter- two or more well-accepted theraests.
pies-therapies that they would reway. If a physician can only recomceive from any number of doctors
mend that a patient volunteer forWe
re-should be wary of measures

search, the physician may be more
that might undermine patient trust.
whom they might see for care.
Because
aggressive with some patients and
less patients lack medical exper- Moreover, conducting research
tise and because the patient's health
that compares established therapies in
aggressive with others in encouraging
order to discover whether one is betand
even life may hang in the balparticipation. Physicians might
put
ter may well bolster patient trust. Pamore pressure on their more vulneraance, patients are highly dependent

their physicians. With so muchtients
at
ble and less powerful patients,on
who
ought to be reassured by knowstake for the patient and so much
ing that their physicians are trying to
are less likely to reject their physifind out which treatments are optician's offers. But if the physician
power
linksin the hands of the physician,
treatment with research participation,
patients will not be willing to rely mal.
on In fact, research on patient re-

luctance to enroll in research trials inthen every patient faces thetheir
samephysicians' judgment unless
dicates that key considerations in the
pressure to enroll in the researchthey
trial.can trust that physicians use

their skills and power on their paIn other words, allowing the physipatient's decision are the physician's
tients' behalf.
enthusiasm for the study and whether
cian to condition treatment on par26 HASTINGS CENTER REPORT
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the physician is truly uncertain about
the value of the different therapies.52

Accordingly, conditioning treatment
on the patient's willingness to enter
the trial can directly respond to patient concerns to the extent that the

physician expresses enthusiasm for
the study and acknowledges uncer-

tainty about how the treatments
compare.

Its Limits: When Research Ethics Can
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Clinical Trials 14 (1993): 38S-51S.
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/Many people have been unneces-

6. See N. Mills et al., "Perceptions of
sarily harmed by research that

16. AFFIRM Investigators, "A Comparison of Rate Control and Rhythm Control

Equipoise Are Crucial to Trial Participation:
did not adhere to sufficientlyAstrict
Qualitative Study of Men in the ProtecT
Study," be
Controlled Clinical Trials 24 (2003):
ethical safeguards. Steps should
272-82, at 273. The effectiveness and side

in Patients with Atrial Fibrillation," 1825-6.

taken to protect against future harm.

effects of a drug or other treatment can be
reasonably well identified only if a substan-

17. A.L. Waldo, "Management of Atrial
Fibrillation: The Need for AFFIRMative

At the same time, ethical safeguards

Action," American Journal of Cardiology 84

can become too strict. Sometimes,

tial number of patients are tested, and it can

important advances in medical
un- to years to enroll the necessary
take months

number.by
derstanding are slowed or stymied
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Atrial Fibrillation Follow-up Inunnecessary limits on the ability
of

(1999): 698-700.

18. AFFIRM Investigators, "A Comparison of Rate Control and Rhythm Control
in Patients with Atrial Fibrillation," 1826.

19. Ibid. Nonpharmacologic therapies

vestigation of Rhythm Management (AFphysicians to encourage their patients
FIRM) Investigators, "A Comparison of
to participate in cinical trials. When

include ablation of the heart cells that gen-

a cinical trial compares two or
more
tients
with Atrial Fibrillation," New Engwell-established therapies to deterlandJournal ofMedicine 347 (2002): 1825-

maze procedure, which involves surgical incisions to control the transmission of the

enroll, about two-thirds of the refusals
ought to be able to condition not
treatcame from the patient and one-third from
ment on a patient's willingness to en-

England Journal of Medicine 344 (2001):

Rate Control and Rhythm Control in Pa-

33, at 1826. Of the 3,341 patients who did
mine which is better, physicians

the patients' primary physicians. Personal
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correspondence, Leon Greene, AFFIRM
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